- Endoscopic sleeve gastroplasty (ESG) resulted in nearly 2.5 times more weight loss than oral semaglutide over six months.
- The ESG group achieved an average total body weight loss of 15.8%, compared to 6.4% in the oral semaglutide group.
- ESG is a minimally invasive, incision-free endoscopic procedure offering a potentially transformative option for substantial weight reduction.
- The study suggests structural interventions like ESG may have a distinct advantage over pharmacological approaches in the short term.
- The findings position ESG as a viable alternative to traditional bariatric surgery for weight loss.
Adults with obesity who underwent endoscopic sleeve gastroplasty (ESG) lost nearly two and a half times more weight over six months than those treated with oral semaglutide, according to a comparative study presented at ESGE Days 2026. The trial, which evaluated 120 patients across multiple European centers, revealed an average total body weight loss of 15.8% in the ESG group, compared to just 6.4% among those taking the daily oral medication. These results position ESG—a minimally invasive, incision-free endoscopic procedure—as a potentially transformative option for patients seeking substantial weight reduction without the risks of traditional bariatric surgery. With global obesity rates continuing to climb, affecting over 650 million adults worldwide, the search for effective, scalable treatments has never been more urgent, and this study suggests structural interventions may hold a distinct advantage over pharmacological approaches in the short term.
Why This Matters Now
Obesity has evolved into a global public health crisis, strongly linked to cardiovascular disease, type 2 diabetes, and certain cancers. While medications like semaglutide—marketed as Wegovy and Rybelsus—have revolutionized non-surgical treatment, their efficacy varies, and long-term adherence remains a challenge. Oral semaglutide, though convenient, delivers lower bioavailability than its injectable counterpart, potentially limiting its impact. Meanwhile, endoscopic procedures such as ESG are gaining traction as “metabolic endosurgeries” that mimic the stomach-restrictive effects of bariatric surgery without general anesthesia or prolonged recovery. The timing of this head-to-head comparison is critical, as healthcare systems weigh cost, accessibility, and patient eligibility across treatment tiers. With obesity management shifting toward earlier, more aggressive interventions, data directly comparing these modalities provide much-needed clarity for clinicians and patients alike.
What the Study Found
The prospective, multicenter trial directly compared outcomes in two matched cohorts: one undergoing ESG and another receiving daily oral semaglutide at the standard 14 mg dose. All participants had a baseline BMI between 30 and 40 kg/m² and were enrolled in structured lifestyle programs. ESG involves placing sutures endoscopically to reduce stomach volume, effectively creating a sleeve-like structure. The procedure takes about 60 minutes and typically requires only sedation. In contrast, the semaglutide group received six months of daily medication with monthly follow-ups. After six months, the ESG cohort achieved a mean weight loss of 15.8%, while the pharmacotherapy group achieved 6.4%. Notably, 78% of ESG patients lost at least 10% of their body weight, compared to 32% in the medication group. Minor adverse events, such as transient nausea or abdominal pain, occurred in both groups but were generally self-limiting.
Analysis of Efficacy and Mechanisms
The substantial difference in weight loss outcomes can be attributed to both anatomical and behavioral factors. ESG physically limits gastric capacity, leading to earlier satiety and reduced caloric intake, whereas oral semaglutide works pharmacologically by mimicking GLP-1, a hormone that regulates appetite and insulin. However, the drug’s lower systemic absorption when taken orally—estimated at around 1% bioavailability—may undercut its effectiveness compared to injectable formulations, which achieve up to 80% higher plasma concentrations. Additionally, patient adherence to daily oral medication, though generally high in trials, tends to decline in real-world settings. The ESG procedure, in contrast, offers a one-time intervention with sustained anatomical effects, though it requires specialized training and endoscopic expertise. According to the study’s lead investigator, “ESG creates a durable physiological change, whereas medication effects are reversible upon discontinuation.” Data also showed greater improvements in waist circumference and insulin resistance in the ESG group, suggesting broader metabolic benefits.
Implications for Patients and Providers
These findings could reshape treatment pathways for obesity, particularly for patients who are not candidates for bariatric surgery or who fail to respond adequately to medications. ESG may serve as a valuable middle ground—more effective than drugs and less invasive than surgery. However, access remains limited; the procedure is currently available at only a few specialized centers in Europe and the United States. Cost is another barrier: ESG can range from $15,000 to $25,000 out-of-pocket, whereas oral semaglutide, though expensive, may be partially covered by insurance. Still, for motivated patients seeking rapid, significant weight loss, ESG presents a compelling alternative. Primary care providers may need to reconsider referral patterns, especially as endoscopic techniques become more widespread and training programs expand.
Expert Perspectives
Experts are divided on how to interpret the results. Dr. Lena Moretti, a metabolic endoscopist at University Hospital Zurich, praised the study, stating, “This is the first real-world comparison showing ESG’s superiority over oral GLP-1 agonists.” She believes such procedures should be integrated earlier into obesity care algorithms. Conversely, Dr. Rajiv Patel, an endocrinologist at King’s College London, cautioned against overgeneralization: “Medications are scalable and accessible. We shouldn’t reserve effective tools based on a six-month trial.” He emphasized that long-term data on ESG durability are still emerging, while GLP-1 drugs have demonstrated cardiovascular benefits in large randomized trials. Both agree, however, that combination therapies—using medication post-ESG to maintain weight loss—deserve further study.
Looking ahead, researchers plan longer-term follow-up to assess weight regain and metabolic outcomes beyond one year. Ongoing trials are also exploring hybrid approaches, such as using semaglutide after ESG to enhance and sustain results. As obesity treatment becomes increasingly personalized, the balance between procedural and pharmacological options will depend on patient profiles, healthcare infrastructure, and cost-effectiveness. One key question remains: can ESG’s early success translate into lasting health improvements at a population level? With more data on the horizon, the answer may redefine how medicine tackles one of its most persistent challenges.
Source: MedicalXpress